News

According to Galderma, approval is based on positive results from the phase 3 ARCADIA clinical trial program.

"I really hope this becomes a first-line agent that people are comfortable prescribing whether they are in dermatology, pediatric dermatology, or primary care."

A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.

The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.

In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.

Pharming Group N.V. plans to include these findings in worldwide regulatory filings in 2025.

A good correlation and statistical agreement with total serum bilirubin was observed in a study of a new smartphone-based machine learning app, leaving it a potential neonatal jaundice screening tool.

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

The submission to treat PsO is for children aged 6 years and up while the jPsA submission is to treat children aged 5 years and older.

Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.

Respondents reported decreased diarrhea severity, improved patient quality of life, and decreased treatment discontinuation among patients with Rett syndrome treated with trofinetide.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Results demonstrated that those with earlier asthma onset had slower development of episodic memory.

A new study highlights how depression may drive dysmenorrhea through shared genetic pathways, emphasizing the need for mental health screening and holistic care for women.

In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.

101-PGC-005 is Type IA prodrug of dexamethasone that targets CD206+ macrophages.

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Practicing gratitude boosts wellbeing, improves sleep, and reduces stress. Parents can foster it daily by modeling gratitude, helping others, and reflecting on positives.

The most common reactions reported were the following: irritability or fussiness (30.1%), local reactions (21.1%) and fever (13.8%).

Results demonstrated that slowed aperiodic activity was present in brain areas linked to concussion symptoms such as impaired concentration and memory.

Paul Kruszka, MD, MPH, FACMG, explains for general providers the difference between screening and diagnosis regarding whole genome sequencing and how it could play a role in the primary care setting.

In this video interview, Herbert Bravo, MD, explains how implementing autoimmune diabetes screenings in the primary care setting can benefit the child several ways.

A recent study suggests the ketogenic diet could positively impact menstrual cycles by boosting ketones, potentially unlocking new therapeutic insights for women’s reproductive health.

Contemporary Pediatrics' editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the recent uptick in pediatric vaccine exemptions in this video interview.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Reportedly, the child experienced mild symptoms and has received flu antivirals.